Fetal loss induced by antiphospholipid antibodies (aPLs) in mice is a complement-driven inflammatory condition. Engagement of the complement receptor C5aR on neutrophils induces expression of the principal initiator of the blood clotting mechanism, tissue factor (TF), and blocking this downstream event of complement activation prevents antibody-induced fetal loss. In this issue of the JCI, the study by Redecha et al. clarifies that in mice, the contribution of TF to this pathogenic mechanism is independent of its role in coagulation and thrombosis, but involves inflammatory signaling through the receptor PAR2 (see the related article beginning on page 3453). The study not only sheds light on a critical effector mechanism of aPL-induced fetal loss, but also suggests that treatment with statins, which decrease TF and PAR2 expression, may hold promise as a therapeutic approach to antiphospholipid syndrome–associated pregnancy complications.

Antiphospholipid syndrome (APS) is characterized by the presence of autoreactive antiphospholipid antibodies (aPLs), which recognize specific plasma proteins that possess an affinity for anionic phospholipids, combined with clinical evidence of thrombosis. In pregnant females, aPLs trigger severe pregnancy complications, such as miscarriage, intrauterine growth restriction, and fetal death, and also increase the likelihood of preeclampsia (1–3). Infusion of aPLs isolated from human patients into pregnant mice is sufficient to reproduce fetal loss and fetal growth restriction. A remarkable series of genetic and pharmacologic intervention studies in this mouse model has led to a detailed understanding of the pathogenesis underlying aPL-induced fetal loss (1, 4, 5).

Clinically, the most relevant antigen recognized by aPLs is β2-glycoprotein I (β2GPI), a plasma protein with poorly characterized functions. Binding of aPL induces the formation of β2GPI dimers with increased affinity for anionic phospholipids. Binding to negatively charged membrane surfaces is also essential for the function of key coagulation proteins, including prothrombin. Competition between aPL/β2GPI complexes and coagulation factors for binding to phosphatidylserine explains the anticoagulant effect exerted by aPLs in vitro coagulation assays. The affinity for negatively charged membranes directs the selective allocation of aPL/β2GPI complexes to the phosphatidylserine-rich surface of fetal trophoblast cells in the placenta.

A critical milestone in understanding aPL-induced fetal loss was the observation of massive accumulation of complement component C3 in the placenta and the finding that that genetic deficiency of maternal C3 or administration of the C3 inhibitor Cryy-IgG prevents fetal loss (6). It has since been shown that downstream of C3 in this signaling pathway, interactions between complement component C5a and the C5a receptor (C5aR), rather than the classic cell-destructing formation of the C5b-C9 membrane attack complex, are responsible for fetal loss (7).

Thus far, 2 specific consequences of C5a-C5aR engagement are known to contribute to fetal loss: augmented release of TNF-α and induction of tissue factor (TF) expression by maternal neutrophils (9). TNF-α may exert direct cytotoxic effects on trophoblast cells that line maternal blood spaces in the placenta, or sustain the activation of immune cells in the placenta. Accordingly, genetic ablation or functional inhibition of TNF-α and its interactions with its receptors prevents aPL-induced fetal loss (8). More recent work shows that the aPL-induced expression of TF on neutrophils is a critical second link between C5aR engagement and fetal loss (9). C5aR-deficient neutrophils fail to increase TF expression in response to aPL, and pharmacologic or genetic suppression of TF in maternal neutrophils is sufficient to prevent the formation of reactive oxygen species and fetal loss.

**TF mediates fetal loss independent of thrombosis**

In the study by Redecha et al. in this issue of the JCI (10), the authors distinguish the relative role of the 2 known functions of TF. TF is a transmembrane receptor for the circulating coagulation Factor VII (FVII) (11). Upon formation of the TF/FVII complex, TF gains affinity for plasma coagulation Factor X (FX) and converts it—via partial proteolysis—from an inactive zymogen to the active protease form (FXa). After release from the ternary TF/FVIIa/FXa complex, FXa assembles with FVα on negatively charged membranes to form the principal enzymatic complex (prothrombinase) driving the generation of thrombin. Formation of the ternary complex of TF, FVIIa, and FX is regulated at the level of TF expression as well as by the redox status of preformed TF (12). With few exceptions, constitutive TF expression is limited to cell types that are sequestered from access to blood and blood components by the endothelial cell barrier of blood vessels. Injury to the endothelial cell barrier facilitates physical contact of TF and FVII and thereby triggers the blood coagulation reaction. Inflammatory mediators compromise endothelial barrier function and induce expression of TF in endothelial cells and various immune cell populations. This activates blood coagulation at sites of inflammation. However, the TF/FVIIa/FXa complex not only initiates coagulation, but can also elicit cellular signaling processes via proteolytic activation of G pro-

**Nonstandard abbreviations used:** a-activated; aPL, antiphospholipid antibody; APS, antiphospholipid syndrome; β2GPI, β2-glycoprotein I; C5aR, C5a receptor; FVII, Factor VII; PAR, protease-activated receptor; TF, tissue factor.

**Conflict of interest:** The author has declared that no conflict of interest exists.

**Citation for this article:** J. Clin. Invest. 118:3276–3278 (2008). doi:10.1172/JCI37243.
Role of TF/PAR2 signaling in aPL-induced fetal loss. Maternal aPLs activate the complement system in the placenta. Engagement of C5aR triggers expression by neutrophils of the blood coagulation initiator TF, resulting in generation of reactive oxygen species, injury to fetal trophoblast cells of the placenta, and ultimately loss of the fetus. TF binds and activates coagulation factors FVII and FX circulating in maternal blood to form the ternary TF/FVIIa/FXa complex. The study by Redecha et al. in this issue of the JCI (10) shows that TF-mediated neutrophil activation proceeds through engagement of PAR2 via this initiation complex of blood coagulation. The statin drugs simvastatin and pravastatin prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reactive oxygen species and suppressing amplification of complement activation by factors released from neutrophils. Statins may hold promise as a therapeutic approach to APS-associated pregnancy complications.

Figure 1

Role of TF/PAR2 signaling in aPL-induced fetal loss. Maternal aPLs activate the complement system in the placenta. Engagement of C5aR triggers expression by neutrophils of the blood coagulation initiator TF, resulting in generation of reactive oxygen species, injury to fetal trophoblast cells of the placenta, and ultimately loss of the fetus. TF binds and activates coagulation factors FVII and FX circulating in maternal blood to form the ternary TF/FVIIa/FXa complex. The study by Redecha et al. in this issue of the JCI (10) shows that TF-mediated neutrophil activation proceeds through engagement of PAR2 via this initiation complex of blood coagulation. The statin drugs simvastatin and pravastatin prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reactive oxygen species and suppressing amplification of complement activation by factors released from neutrophils. Statins may hold promise as a therapeutic approach to APS-associated pregnancy complications.

aPLs and thrombosis

This stimulating work by Redecha et al. (10) has naturally raised more questions regarding the mechanism of thrombosis caused by aPLs in the absence of pregnancy. As summarized in a recent review (15), inhibition of complement at the level of C3, C5, or C5a ameliorates aPL-induced thrombosis in animal models, clearly implicating complement activation as a contributing factor to the pathogenesis of aPL-mediated thrombophilia (16). However, the picture is probably more complex and may involve TF-independent mechanisms. B2GPI/aPL complexes interact with specific receptors on the surface of platelets, such as the LDL receptor family member ApoE receptor 2/LDLR-related protein 8 and the platelet adhesion receptor GPIbα. Binding to these receptors causes platelet activation (17, 18). These receptors have recently emerged as targets of the key component of the protein C anticoagulant pathway, activated protein C/protein C (19), and the presence of aPL is (at least in a subset of patients) associated with resistance to the anticoagulant activity of activated protein C (non-Leiden activated protein C resistance; ref. 20). Tracing this emerging link between the coagulation mechanism and antibody-mediated inflammation will likely shed more light on the thrombotic pathogenesis of APS.